MoonLake shares jump after AbbVie reports modest hidradenitis trial results
MoonLake Immunotherapeutics stock rose sharply after AbbVie disclosed Phase 3 data for its hidradenitis suppurativa drug lutikizumab, which showed an 8‑point advantage over placebo. MoonLake’s own sonelokimab had previously demonstrated a larger 14‑point gap in a similar endpoint. The company is awaiting FDA review of its biologic, submitted on Sept. 30, with a commercial launch targeted for the second half of 2027.
Why it matters
The stock surge reflects investor optimism that AbbVie’s modest results improve MoonLake’s competitive positioning (the company’s own data showed a larger efficacy gap). The pending FDA decision, expected around late November, will determine whether MoonLake can proceed to market in 2027 (the company says it expects a priority review).
Key facts
- 1MoonLake shares jumped 18% on the day of AbbVie’s announcement. finance.yahoo.com
- 2AbbVie’s lutikizumab achieved a 31.4% HiSCR75 response at week 16 versus 23.4% for placebo, an 8‑point gap. finance.yahoo.com
- 3MoonLake’s sonelokimab showed a 35.4% HiSCR75 response versus 21.6% for placebo in its Phase 3 VELA program, a 14‑point gap. finance.yahoo.com
- 4In pooled Phase 3 data, sonelokimab achieved a 67.2% HiSCR75 response at week 52. tradingview.com
- 5MoonLake submitted its biologics license application on Sept. 30. finance.yahoo.com
- 6MoonLake held $537 million in cash at the end of June. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.